FindTrial
Sign In

Study Evaluating Effexor XR for Major Depression.

Phase III Multi-Center, Double-Blind, Comparative Study of Effexor XR for the Treatment of Depression

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00225511
Enrollment
590
Registered
2005-09-23
Start date
2004-06-30
Completion date
Unknown
Last updated
2007-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression

Brief summary

Study Evaluating Effexor XR for Major Depression.

Interventions

DRUGEffexor XR
DRUGMilnacipran

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
20 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with major depression based on DSM-IV-TR * Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of depressed mood at the baseline.

Exclusion criteria

* Patients with schizophrenia or any other psychotic disorder * Patients with history or presence of bipolar disorder

Design outcomes

Primary

MeasureTime frame
Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy.—

Secondary

MeasureTime frame
Difference of total score of HAM-D17 between baseline and final-on-therapy.—
Remission rate of HAM-D17 at the final-on-therapy.—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026